
Acomplia (Rimonabant) is a medication for correcting obesity and other conditions accompanied with obesity. Its active ingredient is rimonabant. It has been approved for marketing in the territory of European Union and is awaited to be approved for US territory by the brand name Zimulti. The dieting and exercise is recommended along with the treatment.
Acomplia (Rimonabant) is first of its sort and is a new category of therapeutic agent known as Cannabinoid-1 Receptor Blockers (CB1).
Acomplia has a selective blockage action of CBI Receptors, which are present in brain and other organs responsible for Glucose and fat metabolism like adipose tissue, liver, gastro-intestinal tract and muscles.
Acomplia (Rimonabant) has the capability of closing the very brain nervous circuiting which is responsible for making persons feel appetite during the moment they are smoking cannabis.
Besides CB1 receptor blockage with Acomplia (Rimonabant) action is for decreasing the hyperactivity of internal cannabinoid functioning arrangement. This arrangement is very recent observation of physiological function, which include receptors like that of CB1 receptor and it has demonstrated to participate in vital role of regulation of body weight by a control on energy balance. There is an effective control of glucose and fat process of breakdown.
Sanofi has claimed that Acomplia is capable of preventing the risks of cardiovascular disease.
Persons with large waist girth dimensions of 102 cm for men and 88 cm for women shall have maximum benefit by taking the medication of Acomplia (Rimonabant).
Nearly fifty percent of the observation of progress in HDL-cholesterol, triglycerides and HbA1C, HbA1C is indicator of blood sugar control in patients who had taken the dose of Acomplia (Rimonabant, Zimulti)20mg and was independent of the expected on account of weight loss exclusively.
Psychiatric related side effects:
The advice is to discontinue medication with Acomplia (Rimonabant, Zimulti) if there is problem associated with mental health. Not to be taken along with anti-depressants.
It is not suitable in major depressive illness. The side effects observed in the trial with Acomplia for obesity related to vomiting and nausea. 19 % of the persons included in the trial were forced to discontinue participation in the trial as compared to 13 percent of patient discontinuation, who were put on placebo.
The Acomplia (Rimonabant and Zimulti) is available in capsule form, which is red and yellow in, and the recommended dose is one 20mg tablet once a day, before breakfast.
In case of overdose the person should be taken to hospital for management of the condition and the side effects presented.